Study of CM518D1 in Patients With Advanced Solid Tumors
A phase 1/2 trial of CM518D1 in advanced solid tumours, run by Keymed Biosciences Co.Ltd, now recruiting.
Overview
Study of CM518D1 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07019779 by Keymed Biosciences Co.Ltd, with 434 participants planned, started 2025-06-27 and due to reach its primary completion in 2028-12-31. Interventions recorded: CM518D1.
Similar pages
not linked directly; found by shared links- TrialA Study of CM350 in Patients With Advanced Solid Tumors
Shares Keymed Biosciences (KYM Biosciences), Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma
Shares Keymed Biosciences (KYM Biosciences) and the tag pipeline.
- TrialInvestigation of a Therapeutic Vaccine (ACIT-1) in Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPlasmodium Immunotherapy for Advanced Malignant Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialFirst-in-Human Study of ICT01 in Patients With Advanced Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.